MenQuadfi is a vaccine indicated for active immunization for the prevention of invasive
meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. MenQuadfi is approved for
use in individuals 2 years of age and older.1
MenQuadfi does not prevent N. meningitidis serogroup B disease.1
MenQuadfi should not be administered to anyone who has had a severe allergic reaction to any component of the
vaccine, or after a previous dose of MenQuadfi or any other tetanus toxoid-containing vaccine.
Appropriate observation and medical treatment should always be readily available in case of an anaphylactic
event following the administration of the vaccine.
Some individuals with altered immunocompetence, including some individuals receiving immunosuppressant therapy,
may have reduced immune responses to MenQuadfi. Persons with certain complement deficiencies and persons receiving
treatment that inhibits terminal complement activation (eg, eculizumab) are at increased risk for invasive disease
caused by N meningitidis, including invasive disease caused by serogroups A, C, W, and Y, even if they develop
antibodies following vaccination with MenQuadfi.
Syncope can occur following, or even before, vaccination with MenQuadfi. Procedures should be in place to
prevent falling and injury and to manage syncope.
Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another
US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to give MenQuadfi to persons
with a history of GBS should take into account the expected benefits and potential risks.
Immunization with MenQuadfi does not substitute for routine tetanus immunization.
Vaccination with MenQuadfi may not protect all vaccine recipients.
The most common adverse reactions following a primary dose of MenQuadfi in individuals 2 years of age and older
include pain at the injection site; myalgia, headache, and malaise. Other common adverse reactions in children 2
through 9 years of age include erythema and swelling at the injection site. In adolescents and adults, rates of
solicited adverse reactions following a booster dose were comparable to those observed following primary
vaccination. Other adverse reactions may occur.